Carol Davila University of Medicine and Pharmacy

Affluent Medical : Affluent Medical strengthens its management team to support industrial and commercial deployment

Retrieved on: 
Thursday, February 2, 2023
Medtronic, John Ben Kalio, BD (company), Laboratory, Ophthalmology, University, Regulatory News Service, Aix-en-Provence, Marketing, Robotics, Urinary incontinence, Urology, Diabetes, Carol Davila University of Medicine and Pharmacy, General surgery, Gynaecology, Cosmetics, III, Paris, ISIN, Medtech, Life, Inborn errors of metabolism, Medical device, Pharmaceutical industry

Prior to joining Affluent Medical, Claire André held quality management positions in companies developing and marketing class III medical devices.

Key Points: 
  • Prior to joining Affluent Medical, Claire André held quality management positions in companies developing and marketing class III medical devices.
  • Sébastien Ladet, CEO of Affluent Medical, said: "I am delighted that Claire, Olivier and Céline have joined Affluent Medical at a pivotal time in the life of the Group.
  • As we continue the clinical development of our three innovative medical devices, Affluent Medical is actively preparing for the next steps in industrialization and commercial development with a highly experienced and complementary team."
  • Affluent Medical is examining the best financing options to support the next stages of its development.

Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First Monoclonal Antibodies Recommended as a Treatment for COVID-19 by the CHMP

Retrieved on: 
Thursday, November 11, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Regdanvimab, Safety, Associate, South Korea, European, MD, MAA, European Commission, Celltrion, Infection, European Union, Doctor of Philosophy, Terminology, EMA, Inflammation, Union, Severe acute respiratory syndrome coronavirus 2, EC, Carol Davila University of Medicine and Pharmacy, COVID-19, Viral load, Committee for Medicinal Products for Human Use, Forward-looking statement, Hospital, Marketing, RBD, Korea, Committee, Medicine, US, Death, European Directive on Traditional Herbal Medicinal Products, CHMP, Royal commission, Lung, Patient, Risk, EU, Vaccine, Pharmaceutical industry, Audit, Celltrion Healthcare, regdanvimab (CT-P59), CELLTRION HEALTHCARE, REGDANVIMAB (CT-P59)

The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union.

Key Points: 
  • The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union.
  • At Celltrion, we are proud to play our part in tackling the unprecedented global threat of COVID-19 and believe regdanvimab offers an important addition to the treatment arsenal.
  • As of November 2021, more than 21,366 people have been treated with regdanvimab in 127 hospitals in the Republic of Korea.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.

Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

Retrieved on: 
Monday, November 1, 2021
US Food Sovereignty Alliance, Hospital, Disease, Ethics, Conditional sentence, Medication, Breakthrough therapy, Virus, Patient, SEDAR, World Health Organization, FDA, World, Cardiovascular disease, Cell Journal, Ministry, Food, Health Canada, TSX, Leadership, Company, Kingdom, End organ damage, Clinical trial, Standard of care, Intention, CEO, COVID-19, Data lake, BET, Cell, List of health departments and ministries, News, WHO, Publication, Risk, GLOBE, Carol Davila University of Medicine and Pharmacy, Legislation, Gene expression, Pharmaceutical industry

We are pleased to collaborate with the Kingdom of Moroccos Ministry of Health under the leadership of Professor Bouchra Meddah, Director of Medicines and Pharmacy, for the possible launch of COVID-19 clinical studies with our novel epigenetic drug apabetalone.

Key Points: 
  • We are pleased to collaborate with the Kingdom of Moroccos Ministry of Health under the leadership of Professor Bouchra Meddah, Director of Medicines and Pharmacy, for the possible launch of COVID-19 clinical studies with our novel epigenetic drug apabetalone.
  • The Kingdom of Moroccos Ministry of Health is pleased to be collaborating with Resverlogix on this important global initiative that has tragically impacted so many people worldwide.
  • Following Health Canadas approval for Resverlogixs COVID-19 clinical trials, it has been actively working with hospitals and ministries to commence COVID-19 trials globally.
  • On October 12th, 2021, Resverlogix received ethics committee approval for COVID-19 clinical trials in Western Canadian sites.

MiNA Therapeutics Expands Senior Leadership Team With Four New Hires to Support Next Phase of Growth

Retrieved on: 
Tuesday, October 12, 2021
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mina, Lists of diseases, Newcastle University, Harvard Medical School, Therapy, Medical degree, Roche, Doctor of Philosophy, Bioorganic chemistry, Drug discovery, Reproductive immunology, University, Human Immunology, Carol Davila University of Medicine and Pharmacy, Phio Pharmaceuticals, Cell, Growth, Organic Syntheses, Cancer, LNA, CMC, Invention, GlaxoSmithKline, Risk management, RNA, SaRNA, AstraZeneca, Leadership, Lilly, Acquisition, Patient, University of Copenhagen Faculty of Health and Medical Sciences, Research, Technology, Eisai, Copenhagen, Pharmaceutical industry, Fine chemical

MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (saRNA) therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Companys next phase of growth.

Key Points: 
  • MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (saRNA) therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Companys next phase of growth.
  • These appointments include:
    We are thrilled to welcome Troels, Julia, Ilian and Kevin to the MiNA team, which we have been expanding throughout the year to support the Companys continued development.
  • Troels brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building.
  • Most recently working as an independent consultant, Troels led RNA therapeutics research at Roche as Chief Technology Officer and VP Research, Roche Innovation Centre Copenhagen.

Consolidated HCI Holdings Announces Update to Reverse Takeover Transaction with Vaxxinator Enterprises Inc.

Retrieved on: 
Friday, August 27, 2021
NEO Exchange, Company, INOX, Nano, University, CSE, Issuer, Virus, Nature, Bacteria, UL, Person, Government, High, CHCI, Consolidated, TSX Venture Exchange, Canadian Securities Exchange, Forward-looking statement, Carol Davila University of Medicine and Pharmacy, Ferrari, Public health, Board, News, Disclosure, CEO, Essence–energies distinction, Water, IP, Patent, Technology, Mark (given name), Cryptocurrency, Security (finance)

The Shares remain halted for trading and will not commence trading on the CSE until after the completion of the Proposed Transaction.

Key Points: 
  • The Shares remain halted for trading and will not commence trading on the CSE until after the completion of the Proposed Transaction.
  • The Company further announces that Dr. Ion Bazac, a renowned health care expert and former Health Minister of Romania will join the board of directors of the Company upon the completion of the Proposed Transaction.
  • Vaxxinator Enterprises Inc. is a clean tech company driven to bring clean air and water to the world.
  • CHCI undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

MAIA Biotechnology, Inc. Announces Additions to Executive Team and Board of Directors

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Media (communication), Digital, MedImmune, New York University, Book, Insight, Data Analytics Acceleration Library, FKBP4, University of Zambia School of Medicine, Hematology, Strategic planning, Cancer, View, AR, Marketing, Medicine, Internal medicine, Drug development, Hospital, Carol Davila University of Medicine and Pharmacy, Head, Artificial intelligence, Dartmouth, Medical Affairs Bureau, Pharmacyclics, Communication, Therapy, Prudential Financial, MD, SBS, MAIA, HSBC, Growth, Prostate cancer, SBS Swiss Business School, Research, Breast cancer, University, Lead, Vice president, Project, Patient, 2011 New Year Honours (New Zealand), Hematology-Oncology and Stem Cell Transplantation Research Center, Dartmouth–Hitchcock Medical Center, Biotechnology, Yale New Haven Hospital, Forward-looking statement, Pharmaceutical industry

Mihail is a distinguished physician scientist and accomplished drug developer who has brought numerous oncology drugs to patients in need.

Key Points: 
  • Mihail is a distinguished physician scientist and accomplished drug developer who has brought numerous oncology drugs to patients in need.
  • Dr. Obrocea has played an instrumental role in the development and commercialization of numerous drugs, including IMBRUVICA, BESPONSA, and BREYANZI.
  • MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
  • In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.